[
  {
    "ts": null,
    "headline": "Best Dividend Kings: January 2026",
    "summary": "Dividend Kings underperformed SPY in 2025, averaging 4.91% total return versus SPY's 17.72%. Check out the best dividend kings list here.",
    "url": "https://finnhub.io/api/news?id=700ccfed5eefb1d1898514e2ac14a0ad784f86173f841e7a63bfe3b74333dbd9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769379109,
      "headline": "Best Dividend Kings: January 2026",
      "id": 138257731,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2209914068/image_2209914068.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Dividend Kings underperformed SPY in 2025, averaging 4.91% total return versus SPY's 17.72%. Check out the best dividend kings list here.",
      "url": "https://finnhub.io/api/news?id=700ccfed5eefb1d1898514e2ac14a0ad784f86173f841e7a63bfe3b74333dbd9"
    }
  },
  {
    "ts": null,
    "headline": "Merck No Longer in Talks to Buy Revolution Medicines",
    "summary": "The drugmaker had recently been in discussions to acquire RevMed in a deal that could have valued the cancer-drug biotech at around $30 billion.",
    "url": "https://finnhub.io/api/news?id=74963da0a739cd961bc2048f9d6302aa8740314f42280ba3be555461423928f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769369400,
      "headline": "Merck No Longer in Talks to Buy Revolution Medicines",
      "id": 138255814,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The drugmaker had recently been in discussions to acquire RevMed in a deal that could have valued the cancer-drug biotech at around $30 billion.",
      "url": "https://finnhub.io/api/news?id=74963da0a739cd961bc2048f9d6302aa8740314f42280ba3be555461423928f0"
    }
  }
]